Get to know our clinical trials
Dose-escalation and expansion study to evaluate the safety and efficacy of XL092 in combination with immuno-oncology drugs in patients with unresectable advanced or metastatic solid tumors.
THE OBJECTIVE OF THIS STUDY IS TO EVALUATE POTENTIAL NEW CANCER TREATMENTS FOR PEOPLE WITH TUMORS SIMILAR TO YOURS. THE SPONSOR WANTS TO FIND OUT WHAT EFFECTS, POSITIVE OR NEGATIVE, THESE TREATMENTS HAVE ON YOU AND YOUR DISEASE.
Technical Summary
- DOSE-ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF XL092 IN COMBINATION WITH IMMUNO-ONCOLOGY DRUGS IN PATIENTS WITH UNRESECTABLE ADVANCED OR METASTATIC SOLID TUMORS.
- Code EudraCT: 2021-004855-18
- Protocol number: XL092-002
- Promoter: Exelixis, Inc.
- Molecule/Drug: XL092
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.